<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825524</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00721-40</org_study_id>
    <nct_id>NCT02825524</nct_id>
  </id_info>
  <brief_title>Destruction of Residual Endo-biliary Dysplastic Buds After Endoscopic Ampullectomy</brief_title>
  <acronym>endoHPB</acronym>
  <official_title>Efficacy and Safety of Endobiliairy Radiofrequency (Probe Habib TM EndoHPB) for the Destruction of Residual Endo Biliairy Dysplastic Buds After Endoscopic Ampullectomy: Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Cochin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Cochin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and morbidity of biliairy radiofrequency&#xD;
      ablation for the treatment of dysplastic endobiliairy residual lesions (low-grade dysplasia&#xD;
      or high-grade dysplasia) after endoscopic ampullectomy for ampullary adenoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoplastic lesions may persist at the termination of the common bile duct or pancreatic duct,&#xD;
      after endoscopic ampullectomy for adenoma. Such lesions conduct to a difficult therapeutic&#xD;
      problem because surgery (pancreaticoduodenectomy or trans-duodenal resection) has significant&#xD;
      morbidity compared to non-invasive lesions. The use of endoscopic destruction techniques of&#xD;
      dysplastic lesions, including radio-frequency could be an interesting alternative to reduce&#xD;
      the risk of invasive cancer with less morbidity. Ablation with radio-frequency (RF) is a&#xD;
      technique of local tissue destruction in use in many applications, percutaneously or&#xD;
      intraoperatively for the treatment of hepatocellular carcinoma smaller and more recently for&#xD;
      the endoscopic treatment of high-grade dysplasia of Barrett's esophagus. An RF probe has been&#xD;
      developed for an endo-biliary application (Habib EndoHPB, Emcision) and 2 preliminary studies&#xD;
      have reported the use in humans, in the indication of unresectable cholangiocarcinoma. These&#xD;
      two studies have confirmed the feasibility of the technique, with few side effects and&#xD;
      probable anti-tumor efficacy demonstrated by expanding the area of stenosis after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of residual neoplasia</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of low grade dysplasia or high grade dysplasia or invasive carcinoma</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of surgery</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fever</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
    <description>Visual Analogue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
    <description>hematemesis, hematochezia or melena or decreased more than 2 points of hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute pancreatitis</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
    <description>pain and increased of lipase more than 3 fold</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholangitis</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
    <description>fever and abnormal hepatic blood tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perforation</measure>
    <time_frame>48 hours post endoscopic procedure</time_frame>
    <description>pneumoperitoneum, retropneumoperitoneum, pneumothorax</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adenoma, Bile Duct</condition>
  <arm_group>
    <arm_group_label>Endobiliary radiofrequency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Habib™ EndoHBP</intervention_name>
    <description>During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.</description>
    <arm_group_label>Endobiliary radiofrequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of lesions of low-grade dysplasia (LGD) or high grade (HGD) in the common&#xD;
             bile duct, confirmed by two pathological readings in relation to residual adenomatous&#xD;
             tissue into the common bile duct after endoscopic ampullectomy for ampullome conducted&#xD;
             in the previous year&#xD;
&#xD;
          -  Lack of residual adenomatous lesion on the duodenal side after ampullectomy and&#xD;
             possibly additional procedures (endoscopic mucosal resection or argon plasma).&#xD;
             (excluding other duodenal adenomatous lesions in the context of familial adenomatous&#xD;
             polyposis&#xD;
&#xD;
          -  Consultative multidisciplinary digestive cancer meeting confirming the indication of&#xD;
             treatment with endo-biliary radio-frequency&#xD;
&#xD;
          -  Dysplastic lesions extending over 20 mm length maximum in the common bile duct&#xD;
&#xD;
          -  Patients aged ≥ 18 years old and ≤ 85 years old&#xD;
&#xD;
          -  Patients who consented to participate in the study&#xD;
&#xD;
          -  No anesthesia contraindication (ASA 1,2,3)&#xD;
&#xD;
          -  Patient affiliated to a social security scheme (beneficiary or legal)&#xD;
&#xD;
          -  Lack of pregnancy and contraception being women age procreate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lesions of invasive carcinoma in a patient whose clinical condition allows to consider&#xD;
             a pancreaticoduodenectomy&#xD;
&#xD;
          -  Endo-biliary dysplastic lesions diffuse or multifocal&#xD;
&#xD;
          -  Presence of non extractable metal biliary expansive prosthesis&#xD;
&#xD;
          -  History of pancreaticoduodenectomy or hepaticojejunostomy anastomosis&#xD;
&#xD;
          -  Impassable stenosis of the common bile duct&#xD;
&#xD;
          -  Severe coagulopathy, thrombocytopenia &lt; 75,000 G/L , Clopidogrel treatment impossible&#xD;
             to stop temporarily&#xD;
&#xD;
          -  Anesthesia contraindication ( ASA 4)&#xD;
&#xD;
          -  Pace maker or other active implantable medical device&#xD;
&#xD;
          -  Inability to obtain informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>August 25, 2017</last_update_submitted>
  <last_update_submitted_qc>August 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Cochin</investigator_affiliation>
    <investigator_full_name>Frederic PRAT</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Adenoma, Bile Duct</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

